Pacific Biosciences of California PACB Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Pacific Biosciences of California’s reported figures.
Based on trailing twelve months.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's return on equity?
- Pacific Biosciences of California (PACB) reported return on equity of -273.6% in Q1 2026.
- How has Pacific Biosciences of California's return on equity changed year-over-year?
- Pacific Biosciences of California's return on equity decreased by 53.5% year-over-year, from -178.3% to -273.6%.
- What is the long-term trend for Pacific Biosciences of California's return on equity?
- Over 5 years (2020 to 2025), Pacific Biosciences of California's return on equity has grown at a 69.9% compound annual growth rate (CAGR), from 15.1% to -213.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.